255 related articles for article (PubMed ID: 30790095)
1. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
Alten R; Mariette X; Lorenz HM; Nüßlein H; Galeazzi M; Navarro F; Chartier M; Heitzmann J; Poncet C; Rauch C; Le Bars M
Clin Rheumatol; 2019 May; 38(5):1413-1424. PubMed ID: 30790095
[TBL] [Abstract][Full Text] [Related]
2. Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.
Alten R; Feist E; Lorenz HM; Nüßlein H; Voll RE; Chartier M; Elbez Y; Rauch C
Clin Rheumatol; 2019 Nov; 38(11):3049-3059. PubMed ID: 31300979
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
BMC Musculoskelet Disord; 2015 Jul; 16():176. PubMed ID: 26228643
[TBL] [Abstract][Full Text] [Related]
4. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.
Alten R; Mariette X; Flipo RM; Caporali R; Buch MH; Patel Y; Marsal S; Sanmartí R; Nurmohamed MT; Griffiths H; Peichl P; Bannert B; Chartier M; Connolly SE; Lozenski K; Rauch C
Clin Rheumatol; 2022 Aug; 41(8):2361-2373. PubMed ID: 35536413
[TBL] [Abstract][Full Text] [Related]
5. Real-world predictors of 12-month intravenous abatacept retention in patients with rheumatoid arthritis in the ACTION observational study.
Alten R; Mariette X; Lorenz HM; Galeazzi M; Cantagrel A; Nüßlein HG; Chartier M; Elbez Y; Rauch C; Le Bars M
RMD Open; 2017; 3(2):e000538. PubMed ID: 29435360
[TBL] [Abstract][Full Text] [Related]
6. Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.
Peichl P; Alten R; Galeazzi M; Lorenz HM; Nüßlein H; Navarro F; Elbez Y; Chartier M; Hackl R; Rauch C; Connolly SE
Wien Med Wochenschr; 2020 Apr; 170(5-6):132-140. PubMed ID: 31654156
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and prognostic factors of treatment retention with intravenous abatacept for rheumatoid arthritis: 24-month results from an international, prospective, real-world study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Peichl P; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
Clin Exp Rheumatol; 2016; 34(3):489-99. PubMed ID: 26966919
[TBL] [Abstract][Full Text] [Related]
8. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Boumpas D; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Rainer F; Pavelka K; Chartier M; Poncet C; Rauch C; Bars ML
BMC Musculoskelet Disord; 2014 Jan; 15():14. PubMed ID: 24410774
[TBL] [Abstract][Full Text] [Related]
9. Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry.
Choquette D; Bessette L; Alemao E; Haraoui B; Postema R; Raynauld JP; Coupal L
Arthritis Res Ther; 2019 Jun; 21(1):138. PubMed ID: 31171024
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous abatacept for the treatment of rheumatoid arthritis in routine clinical practice in Germany, Austria, and Switzerland: 2-year retention and efficacy by treatment line and serostatus.
Alten R; Tony HP; Bannert B; Nüßlein H; Rauch C; Connolly SE; Chartier M; Lozenski K; Hackl R; Forster A; Peichl P
Clin Rheumatol; 2023 Sep; 42(9):2321-2334. PubMed ID: 37314665
[TBL] [Abstract][Full Text] [Related]
11. Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).
Iannone F; Courvoisier DS; Gottenberg JE; Hernandez MV; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Choquette D; Finckh A
Clin Rheumatol; 2017 Apr; 36(4):773-779. PubMed ID: 27966068
[TBL] [Abstract][Full Text] [Related]
12. The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
Mariette X; Alten R; Nüßlein HG; Galeazzi M; Lorenz HM; Cantagrel A; Chartier M; Poncet C; Rauch C; Le Bars M
Joint Bone Spine; 2017 Oct; 84(5):571-576. PubMed ID: 28043761
[TBL] [Abstract][Full Text] [Related]
13. Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study.
Westhovens R; Connolly SE; Margaux J; Vanden Berghe M; Maertens M; Van den Berghe M; Elbez Y; Chartier M; Baeke F; Robert S; Malaise M
Rheumatol Int; 2020 Sep; 40(9):1409-1421. PubMed ID: 32556473
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors.
Westhovens R; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Helfrick R; Bathon J
Ann Rheum Dis; 2009 Dec; 68(12):1870-7. PubMed ID: 19124524
[TBL] [Abstract][Full Text] [Related]
15. Two-year abatacept retention rate in clinical practice in the French ACTION cohort.
Mariette X; Schaeverbeke T; Gaudin P; Chartier M; Heitzmann J; Vannier-Moreau V; Hilliquin P; Cantagrel A
Joint Bone Spine; 2019 Nov; 86(6):753-759. PubMed ID: 31352138
[TBL] [Abstract][Full Text] [Related]
16. Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry.
Lin CT; Huang WN; Tsai WC; Chen JP; Hung WT; Hsieh TY; Chen HH; Hsieh CW; Lai KL; Tang KT; Tseng CW; Chen DY; Chen YH; Chen YM
PLoS One; 2021; 16(4):e0250877. PubMed ID: 33930048
[TBL] [Abstract][Full Text] [Related]
17. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting.
Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C
Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602
[TBL] [Abstract][Full Text] [Related]
18. Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors-data from a large national quality register.
Cagnotto G; Willim M; Nilsson JÅ; Compagno M; Jacobsson LTH; Saevarsdottir S; Turesson C
Arthritis Res Ther; 2020 Jan; 22(1):15. PubMed ID: 31969172
[TBL] [Abstract][Full Text] [Related]
19. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
Gottenberg JE; Courvoisier DS; Hernandez MV; Iannone F; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Finckh A
Arthritis Rheumatol; 2016 Jun; 68(6):1346-52. PubMed ID: 26815727
[TBL] [Abstract][Full Text] [Related]
20. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.
Ogawa Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Takagi H; Hanabayashi M; Funahashi K; Hayashi M; Tsuboi S; Asai S; Asai N; Matsumoto T; Sobue Y; Ishiguro N; Kojima T
Clin Rheumatol; 2019 Oct; 38(10):2757-2763. PubMed ID: 31179526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
